世界の製薬会社のR&Dディレクトリ 2022年

出版：Asia Pacific InfoServ　出版年月：2022年5月

Global Pharmaceutical R & D Directory 2022

The Global Pharmaceutical R&D Directory provides a wealth of key business data on trends in pharmaceutical research.

※ 印刷版やCD版の価格設定もございます。詳細はお問合せください。

お問合せ・ご注文　　　　価格・納期について

About this product

The Global Pharmaceutical R&D Directory provides a wealth of key business data on trends in pharmaceutical research. At a time when investment in R&D is at an all-time high, this essential publication is intended as a strategic reference guide to the important trends in pharmaceutical R&D, as well as providing the means to benchmark your company’s performance. From an examination of global R&D investment and productivity to a breakdown of R&D trends in every major therapeutic class, The R&D Directory provides a comprehensive review of the current R&D environment. The R&D Directory provides essential time-saving business information on:

• The development pipeline of major companies is analyzed by therapeutic categories and stages
• Compounds in research by therapeutic class for major companies
• Number of licensed compounds by therapeutic class and development stage
• Comparison of companies’ licensed/originated product pipelines
• Average development time to market, and attrition data
• Trends in global R&D investment, cost, and culture
• Number of biotechnology products by development phase, therapeutic class, and type
• Plus much, much more!

Key Features:

• Trends in licensing for major pharmaceutical companies
• R&D Focus for key therapy areas
• Benchmark development time by phase and success for over dozens of therapeutic categories
• Comparisons of compounds in research by development stage for dozens of therapeutic areas
• Analysis of previous year’s pipeline development by stage for all major pharmaceutical companies worldwide.

Contents: Section 1 & 2 of The R&D Directory looks at the trends in R&D expenditure in the major markets, changes in employment patterns and productivity levels in relation to pharmaceutical sales. Section 3 reviews the outsourcing industry and examines its role in pharmaceutical R&D. Section 4 to 9 analyses the trends in R&D by examining the therapeutic focus of selected companies, preclinical compounds, biotechnology compounds, compounds in clinical development for every major therapy class, and licensing activities. Section 10 provides extensive attrition and time-in-development data for the major therapeutic categories. Coverage:

• Western & Eastern Europe incl. UK
• USA & Canada
• South & Central America
• The Middle East
• All of Africa
• All of Asia, including China, India, and Japan
• Australia & New Zealand.

Based on primary research, the 2-volume The R&D Directory provides the most comprehensive assessment of R&D available! Packed with facts, personalities, charts, and statistics, it is presented as a book and also as a fully searchable PDF edition and CD-ROM.